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Risk of bias in translational medicine may take one of three forms: A. a systematic error of methodology as it
pertains to measurement or sampling (e.g., selection bias), B. a systematic defect of design that leads to estimates
of experimental and control groups, and of effect sizes that substantially deviate from true values (e.g., information
bias), and C. a systematic distortion of the analytical process, which results in a misrepresentation of the data with
consequential errors of inference (e.g., inferential bias). Risk of bias can seriously adulterate the internal and the
external validity of a clinical study, and, unless it is identified and systematically evaluated, can seriously hamper the
process of comparative effectiveness and efficacy research and analysis for practice. The Cochrane Group and the
Agency for Healthcare Research and Quality have independently developed instruments for assessing the
meta-construct of risk of bias. The present article begins to discuss this dialectic.Background
As recently discussed in this journal [1], translational
medicine is a rapidly evolving field. In its most recent
conceptualization, it consists of two primary domains:
translational research proper and translational effectiveness.
This distinction arises from a cogent articulation of
the fundamental construct of translational medicine in
particular, and of translational health care in general.
The Institute of Medicine’s Clinical Research Roundtable
conceptualized the field as being composed by two
fundamental “blocks”: one translational “block” (T1) was
defined as “…the transfer of new understandings of
disease mechanisms gained in the laboratory into the
development of new methods for diagnosis, therapy,
and prevention and their first testing in humans…”,
and the second translational “block” (T2) was described
as “…the translation of results from clinical studies into
everyday clinical practice and health decision making…”
[2]. These are clearly two distinct facets of one meta-
construct, as outlined in Figure 1. As signaled by
others, “…Referring to T1 and T2 by the same name—
translational research—has become a source of some* Correspondence: fchiappelli@dentistry.ucla.edu
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distribution, and reproduction in any mediumconfusion. The 2 spheres are alike in name only. Their
goals, settings, study designs, and investigators differ…” [3].
For the last five years at least, the Federal responsibil-
ities for “block” T1 and T2 have been clearly delineated.
The National Institutes of Health (NIH) predominantly
concerns itself with translational research proper - the
bench-to-bedside enterprise (T1); the Agency for Health-
care Research Quality (AHRQ) focuses on the result-
translation enterprise (T2). Specifically: “…the ultimate
goal [of AHRQ] is research translation—that is, making
sure that findings from AHRQ research are widely
disseminated and ready to be used in everyday health
care decision-making…” [6]. The terminology of trans-
lational effectiveness has emerged as a means of
distinguishing the T2 block from T1.
Therefore, the bench-to-bedside enterprise pertains
to translational research, and the result-translation en-
terprise describes translational effectiveness. The meta-
construct of translational health care (viz., translational
medicine) thus consists of these two fundamental con-
structs: translational research and translational effect-
iveness, which have distinct purposes, protocols and
products, while both converging on the same goal of
new and improved means of individualized patient-
centered diagnostic and prognostic care.
It is important to note that the U.S. Patient Protection
and Affordable Care Act (PPACA, 23 March 2010) has
created an environment that facilitates the pursuit of
translational health care because it emphasizes patient-entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Schematic representation of the meta-construct of translational health care in general, and translational medicine in
particular, which consists of two fundamental constructs: the T1 “block” (as per Institute of Medicine's Clinical Research Roundtable
nomenclature), which represents the transfer of new understandings of disease mechanisms gained in the laboratory into the
development of new methods for diagnosis, therapy, and prevention as well as their first testing in humans, and the T2 “block”, which
pertains to translation of results from clinical studies into everyday clinical practice and health decision making [3]. The two “blocks” are
inextricably intertwined because they jointly strive toward patient-centered research outcomes (PCOR) through the process of comparative
effectiveness and efficacy research/review and analysis for clinical practice (CEERAP). The domain of each construct is distinct, since the “block”
T1 is set in the context of a laboratory infrastructure within a nurturing academic institution, whereas the setting of “block” T2 is typically
community-based (e.g., patient-centered medical/dental home/neighborhoods [4]; “communities of practice” [5]).
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fosters the transaction between translational research (i.e.,
“block” T1) and translational effectiveness (i.e., “block”
T2), and favors the establishment of communities of
practice-research interaction. The latter, now recognized
as practice-based research networks, incorporate three
or more clinical practices in the community into a
community of practices network coordinated by an
academic center of research.
Practice-based research networks may be a third “block”
(T3) in translational health care and they could be con-
ceptualized as a stepping-stone, a go-between bench-
to-bedside translational research and result-translation
translational effectiveness [7]. Alternatively, practice-
based research networks represent the practical entities
where the transaction between translational research and
translational effectiveness can most optimally be under-
taken. It is within the context of the practice-based
research network that the process of bench-to-bedside
can best seamlessly proceed, and it is within the frame-
work of the practice-based research network that the
best evidence of results can be most efficiently trans-
lated into practice and be utilized in evidence-based
clinical decision-making, viz. translational effectiveness.
Translational effectiveness
As noted, translational effectiveness represents the transla-
tion of the best available evidence in the clinical practiceto ensure its utilization in clinical decisions. Translational
effectiveness fosters evidence-based revisions of clinical
practice guidelines. It also encourages effectiveness-fo-
cused, patient-centered and evidence-based clinical de-
cision-making. Translational effectiveness rests not only
on the expertise of the clinical staff and the empowerment
of patients, caregivers and stakeholders, but also, and most
importantly on the best available evidence [8].
The pursuit of the best available evidence is the foun-
dation of translational effectiveness and more generally
of translational medicine in evidence-based health care.
The best available evidence is obtained through a sys-
tematic process driven by a research question/hypoth-
esis that is articulated about clearly stated criteria that
pertain to the patient (P), the interventions (I) under
consideration (C), for the sought clinical outcome (O),
within a given timeline (T) and clinical setting (S). PI-
COTS is tested on the appropriate bibliometric sample,
with tools of measurements designed to establish the
level (e.g., CONSORT) and the quality of the evidence.
Statistical and meta-analytical inferences, often enhanc-
ed by analyses of clinical relevance [9], converge into
the formulation of the consensus of the best available
evidence. Its dissemination to all stakeholders is key
to increase their health literacy in order to ensure
their full participation in the utilization of the best
available evidence in clinical decisions, viz., transla-
tional effectiveness.
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perspective discussed above, translational health care –
is anchored on obtaining the best available evidence,
which emerges from highest quality research. High qual-
ity of research is obtained when errors are minimized.
In an early conceptualization [10], errors in research
were presented as those situations that threaten the
internal and the external validity of a research study –
that is, conditions that impede either the study’s repro-
ducibility, or its generalization. In point of fact, threats
to internal and external validity [10] represent specific
aspects of systematic errors (i.e., bias) in the research
design, methodology and data analysis. Thence emerged a
branch of science that seeks to understand, control and
reduce risk of bias in research.
Risk of bias and the best available evidence
It follows that the best available evidence comes from
research with the fewest threats to internal and to
external validity – that is to say, the fewest systematic
errors: the lowest risk of bias. Quality of research, as
defined in the field of research synthesis [11], has
become synonymous with low bias and contained risk
of bias [12-15].
Several years ago, the Cochrane group embarked on a
new strategy for assessing the quality of research studies
by examining potential sources of bias. Certain original
areas of potential bias in research were identified, which
pertain to (a) the sampling and the sample allocation
process, to measurement, and to other related sources of
errors (reliability of testing), (b) design issues, including
blinding, selection and drop-out, and design-specific
caveats, and (c) analysis-related biases.
A Risk of Bias tool was created (Cochrane Risk of





5. reporting bias, and
6. other research protocol-related biases.
Assessments were made within each domain by one or
more items specific for certain aspects of the domain.
Each items was scored in two distinct steps:
1. the support for judgment was intended to provide a
succinct free-text description of the domain being
queried;
2. each item was scored high, low, or unclear risk of
material bias (defined here as “…bias of sufficient
magnitude to have a notable effect on the results or
conclusions…” [16]).It was advocated that assessments across items in the
tool should be critically summarized for each outcome
within each report. These critical summaries were to in-
form the investigator so that the primary meta-analysis
could be performed either only on studies at low risk of
bias, or for the studies stratified according to risk of
bias [16]. This is a form of acceptable sampling analysis
designed to yield increased homogeneity of meta-analyt-
ical outcomes [17]. Alternatively, the homogeneity of
the meta-analysis can be further enhanced by means of
the more direct quality-effects meta-analysis inferential
model [18].
Clearly, one among the major drawbacks of the
Cochrane Risk of Bias tool is the subjective nature of
its assessment protocol. In an effort to correct for this
inherent weakness of the instrument, the Cochrane
group produced detailed criteria for making judgments
about the risk of bias from each individual item [16].
Moreover, Cochrane recommended that judgments be
made independently by at least two people, with any
discrepancies resolved by discussion [16]. This approach
to increase the reliability of measurement in research
synthesis protocols is akin to that described by us
[19,20] and by AHRQ [21].
In an effort to aid clinicians and patients in making
effective health care related decisions, AHRQ devel-
oped an alternative Risk of Bias instrument for enabling
systematical evaluation of evidence reporting [22]. The
AHRQ Risk of Bias instrument was created to monitor
four primary domains:
1. risk of bias: design, methodology, analysis scoring –
low, medium, high
2. consistency: extent of similarity in effect sizes
across studies within a bibliome scoring –
consistent, inconsistent, unknown
3. directness: unidirectional link between the
interventions of interest and the sought outcome,
as opposed to multiple links in a casual chain
scoring – direct, indirect
4. precision: extent of certainty for estimate of effect
with respect to the outcome scoring – precise,
imprecise In addition, four secondary domains
were identified:a. Dose response association: pattern of a
larger effect with greater exposure
(Present/Not Present/Not Applicable
or Not Tested)
b. Confounders: consideration of confounding
variables (Present/Absent)
c. Strength of association: likelihood that the
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potential confounding factors (Strong/Weak)
d. Publication biasThe AHRQ Risk of Bias instrument is also designed
to yield an overall grade of the estimated risk of bias in
quality reporting:
 Strength of Evidence Grades (scored as high –
moderate - low – insufficient)
This global assessment, in addition to incorporating
the assessments above, also rates:
– major benefit
– major harm
– jointly benefits and harms
– outcomes most relevant to patients, clinicians, and
stakeholders
The AHRQ Risk of Bias instrument suffers from the
same two major limitations as the Cochrane tool:
1. lack of formal psychometric validation as most other
tools in the field [21], and
2. providing a subjective and not quantifiable assessment.
To begin the process of engaging in a systematic dia-
lectic of the two instruments in terms of their respective
construct and content validity, it is necessary to validate
each for reliability and validity either by means of the clas-
sic psychometric theory or generalizability (G) theory,
which allows the simultaneous estimation of multiple
sources of measurement error variance (i.e., facets) whileure 2 Proportion of shared variance in criterion validity (A) and in
escribed. Two raters were trained and standardized [20] with the revis
n previously validated [24]. Each rater independently produced ratings
arate occasions, 1–2 months apart. Pearson correlation coefficient was u
rams to illustrate the intersection between each two sets data used in
resents the proportion of shared variance for that correlation. The percegeneralizing the main findings across the different study
facets. G theory is particularly useful in clinical care ana-
lysis of this type, because it permits the assessment of the
reliability of clinical assessment pro-tocols. The reliability
and minimal detectable changes across varied combina-
tions of these facets are then simply calculated [23]. How-
ever, it is recommended that G theory determination
follow classic theory psychometric assessment.
Therefore, we have commenced a process of revision
the AHRQ Risk of Bias instrument by rendering ques-
tions in primary domains quantifiable (scaled 1–4), which
established the intra-rater reliability (r = 0.94, p < 0.05),
and the criterion validity (r = 0.96, p < 0.05) for this instru-
ment (Figure 2).
A similar revision of the Cochrane Risk of Bias tool may
also yield promising validation data. G theory validation of
both tools will follow. Together, these results will enable a
critical and systematic dialectical comparison of the
Cochrane and the AHRQ Risk of Bias measures.Discussion
The critical evaluation of the best available evidence is
critical to patient-centered care, because biased research
findings are fundamentally invalid and potentially harmful
to the patient. Depending upon the tool of measurement,
the validity of an instrument in a study is obtained by
means of criterion validity through correlation coeffi-
cients. Criterion validity refers to the extent to which one
measures or predicts the value of another measure or
quality based on a previously well-established criterion.
There are other domains of validity such as: construct
validity and content validity that are rather more descrip-
tive than quantitative. Reliability however is used toter-rater reliability (B) in the AHRQ Risk of Bias instrument revised
ed AHRQ Risk of Bias and with the R-Wong instrument, which has
on a sample of research reports with both instruments on two
sed to compute the respective associations. The figure shows Venn
the correlations. The overlap between the sets in each panel
nt of unexplained variance is given in the insert of each panel.
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a measurement is repeatable. It is commonly assessed
quantitatively by correlation coefficients. Inter-rater reli-
ability is rendered as a Pearson correlation coefficient
between two independent readers, and establishes equiva-
lence of ratings produced by independent observers or
readers. Intra-rater reliability is determined by repeated
measurement performed by the same subject (rater/
reader) at two different points in time to assess the correl-
ation or strength of association of the two sets of scores.
To establish the reliability of research quality assess-
ment tools it is necessary, as we previously noted [20]:
 a) to train multiple readers in sharing a common view
for the cognitive interpretation of each item. Readers
must possess declarative knowledge a factual form of
information known to be static in nature a certain
depth of knowledge and understanding of the facts
about which they are reviewing the literature. They
must also have procedural knowledge known as
imperative knowledge that can be directly applied to a
task in this case a clear understanding of the
fundamental concepts of research methodology,
design, analysis and inference.
 b) to train the readers to read and evaluate the quality
of a set of papers independently and blindly. They
must also be trained to self-monitor and self-assess
their skills for the purpose of insuring quality control.
 c) to refine the process until the inter-rater correlation
coefficient and Cohen coefficient of agreement are
about 0.9 (over 81% shared variance). This will
establishes that the degree of attained agreement
among well-trained readers is beyond chance.
 d) to obtain independent and blind reading
assessments from readers on reports under study.
 e) to compute means and standard deviation of
scores for each question across the reports, repeat
process if the coefficient of variations are greater
than 5% (i.e., less than 5% error among the readers
across each questions).
The quantification provided by instruments validated in
such a manner to assess the quality and the relative lack
of bias in the research evidence allows for the analysis of
the scores by means of the acceptable sampling protocol.
Acceptance sampling is a statistical procedure that uses
statistical sampling to determine whether a given lot, in this
case evidence gathered from an identified set of published
reports, should be accepted or rejected [12,25]. Acceptable
sampling of the best available evidence can be obtained by:
 convention: accept the top 10 percentile of papers
based on the score of the quality of the evidence
(e.g., low Risk of Bias); confidence interval (CI95): accept the papers whose
scores fall at of beyond the upper confidence limit at
95%, obtained with mean and variance of the scores
of the entire bibliome;
 statistical analysis: accept the papers that sustain
sequential repeated Friedman analysis.
To be clear, the Friedman test is a non-parametric
equivalent of the analysis of variance for factorial de-
signs. The process requires the 4-E process outlined
below:
 establishing a significant Friedman outcome, which
indicates significant differences in scores among the
individual reports being tested for quality;
 examining marginal means and standard deviations
to identify inconsistencies, and to identify the
uniformly strong reports across all the domains
tested by the quality instrument
 excluding those reports that show quality weakness
or bias
 executing the Friedman analysis again, and repeating
the 4-E process as many times as necessary, in a
statistical process akin to hierarchical regression, to
eliminate the evidence reports that exhibit egregious
weakness, based on the analysis of the marginal
values, and to retain only the group of report that
harbor homogeneously strong evidence.
Taken together, and considering the domain and the
structure of both tools, expectations are that these ana-
lyses will confirm that these instruments are two related
entities, each measuring distinct aspects of bias. We
anticipate that future research will establish that both
tools assess complementary sub-constructs of one and
the same archetype meta-construct of research quality.
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